Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer
- 1 January 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (1), 44-53
- https://doi.org/10.1200/jco.2001.19.1.44
Abstract
PURPOSE: To determine the safety and activity of weekly paclitaxel in combination with estramustine and carboplatin (TEC) in patients with advanced prostate cancer. PATIENTS AND METHODS: In a dose-...Keywords
This publication has 23 references indexed in Scilit:
- Clinical states in prostate cancer: toward a dynamic model of disease progressionUrology, 2000
- Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.Journal of Clinical Oncology, 1997
- Clinical Trials in Relapsed Prostate Cancer: Defining the TargetJNCI Journal of the National Cancer Institute, 1996
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994
- P-glycoprotein Binding and Modulation of the Multidrug-Resistant Phenotype by EstramustineJNCI Journal of the National Cancer Institute, 1994
- Carboplatin in advanced hormone refractory prostatic cancer patientsEuropean Journal Of Cancer, 1993
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic CancerJournal of Urology, 1992
- Reporting results of cancer treatmentCancer, 1981